BCV
NTLA icon

Banque Cantonale Vaudoise’s Intellia Therapeutics NTLA Stock Holding History

Banque Cantonale Vaudoise’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-35
Closed -$281K – 1266
2021
Q1 		$281K Buy
+35
New +$2.35K 0.01% 693

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Banque Cantonale Vaudoise's NTLA Position: Q3 2022 in Review

Banque Cantonale Vaudoise sold out of Intellia Therapeutics (NTLA) in Q3 2022, closing a stake of 415 shares — an estimated $21K sold.

Banque Cantonale Vaudoise first reported a position in NTLA in Q3 2020 and held it in 6 quarters. The position peaked at $56K in Q3 2021. 319 funds tracked by Wall St. Rank hold NTLA as of Q3 2022.

  • Banque Cantonale Vaudoise reported no remaining Intellia Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Banque Cantonale Vaudoise sold 415 Intellia Therapeutics shares in Q3 2022, an estimated $21K.
  • Banque Cantonale Vaudoise first reported a position in Intellia Therapeutics in Q3 2020 and held it in 6 quarters.
  • Banque Cantonale Vaudoise's Intellia Therapeutics position peaked at $56K in Q3 2021.
  • 319 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2022.

Based on Banque Cantonale Vaudoise's 13F filing for Q3 2022, filed 17 Oct 2022.